<DOC>
	<DOCNO>NCT00927498</DOCNO>
	<brief_summary>The main objective study compare conventional chemotherapy : daunorubicin Aracytine chemotherapy combination monoclonal antibody use Mylotarg divide dos .</brief_summary>
	<brief_title>A Randomized Study Gemtuzumab Ozogamicin ( GO ) With Daunorubicine Cytarabine Untreated Acute Myeloid Leukemia ( AML ) Aged 50-70 Years Old</brief_title>
	<detailed_description>Patients morphologically proven diagnosis AML two follow criterion : - Age &gt; 50 year £ 70 year . - Not previously treat disease . Randomization centralize phone : Arm A chemotherapy daunorubicin Aracytine Arm B Daunorubicin Aracytine Mylotarg .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients morphologically proven diagnosis AML two follow criterion : Age &gt; 50 year £ 70 year . Not previously treat disease . ECOG performance status 0 3 Negative serology HIV , HBV HBC ( except post vaccination ) Serum creatinin inf 2.5N ; AST ALT inf 2.5N ; total bilirubin inf 2N Cardiac function determine radionucleide echography within normal limit . Negative serum pregnancy test within one week treatment woman child bear potential . Signed informed consent . M3AML AML follow previously know myeloproliferative syndrome . Known central nervous system involvement . Uncontrolled infection Other active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acute myeloid Leukemia</keyword>
	<keyword>patient age 50 70 year</keyword>
</DOC>